GlassScriptPhysician profile
Judith Joyce Luck
NPI 1134317530
$2,482.99
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
See the full distribution for Oncology (Clinical Nurse Specialist)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,396 · 2022: $471 · 2023: $372 · 2024: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $616.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $615.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $374.67 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $346.90 | 2022-2023 | Reblozyl |
| Genentech USA, INC. | $289.97 | 2021 | |
| Glaxosmithkline, LLC. | $249.91 | 2021-2022 | |
| Janssen Biotech, INC. | $236.95 | 2021-2023 | Darzalex, Carvykti, Tecvayli |
| Exelixis INC. | $134.94 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.01 | 2021 | |
| Beigene USA, INC. | $125.00 | 2023 | Brukinsa |
| Genmab U.S., INC. | $121.87 | 2024 | Epkinly |
| Regeneron Healthcare Solutions, INC. | $121.81 | 2024 | Libtayo |
| Kyowa Kirin, INC. | $119.14 | 2021 | |
| Seagen INC. | $118.83 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $117.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judith Luck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.